5-(benzylsulfanyl)-1-methyl-1H-pyrazole-4-carboxylic acid | 111493-56-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(benzylsulfanyl)-1-methyl-1H-pyrazole-4-carboxylic acid
• 英文别名: 5-Benzylthio-1-methylpyrazole-4-carboxylic acid；5-benzylsulfanyl-1-methylpyrazole-4-carboxylic acid
• CAS: 111493-56-2
• 化学式: C₁₂H₁₂N₂O₂S
• 分子量: 248.305
• InChiKey: LPFIATHFSAQRMC-UHFFFAOYSA-N

物化性质

• 熔点：
  82-83 °C
• 沸点：
  439.8±40.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  80.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(benzylsulfanyl)-1-methyl-1H-pyrazole-4-carboxylic acid 生成 5-benzylsulfanyl-1-methylpyrazole-4-carboxamide
  参考文献：
  名称：

  DANTSUDZI, XIROKADZU;IVANAGA, KOITI;NAGASEH, XIROMOTO;JOSIKAVA, XARUTOSI

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl 5-(benzylsulfanyl)-1-methyl-1H-pyrazole-4-carboxylate 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 15.0h， 以84%的产率得到5-(benzylsulfanyl)-1-methyl-1H-pyrazole-4-carboxylic acid
  参考文献：
  名称：

  [EN] PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS
  [FR] DÉRIVÉS DE PYRAZOLE UTILES EN TANT QU'INHIBITEURS (FLAP) DE PROTÉINE ACTIVANT LA 5-LIPOXYGÉNASE

  摘要：

  本申请涉及到式(I)的新化合物，以及它们在治疗和/或预防心血管疾病（CVD）等临床疾病方面的用途，以及它们的治疗用途方法，含有它们的药物组合物以及制备这些化合物的过程。

  公开号：

  WO2016177703A1

文献信息

• Pyrazole Sulfonylurea Compound and Herbicide
  申请人：Kita Hiroshi

  公开号：US20080064600A1

  公开（公告）日：2008-03-13

  There is provided a novel herbicide. A pyrazole sulfonylurea compound of formula (1): wherein R 1 is C 1-3 alkyl, etc., R 2 is hydrogen atom, C 1-3 alkyl, C 1-3 haloalkyl, etc., R 3 , R 4 , R 5 and R 6 independently of one another are hydrogen atom, C 1-3 alkyl, etc., with a proviso that at least one of R 3 , R 4 , R 5 and R 6 is C 1-3 alkyl or C 1-3 haloalkyl, X and Y independently of each other are C 1-3 alkyl, etc., Z is nitrogen atom or methyne, and a salt thereof that is acceptable as an agrochemical; an agrochemical containing at least one of the compound and the salt thereof that is acceptable as an agrochemical as an active component, and a herbicide containing at least one of the compound and the salt thereof that is acceptable as an agrochemical as an active component.

  提供了一种新型除草剂。化合物为吡唑磺酰脲类，其化学式为(1)：其中，R1为C1-3烷基等；R2为氢原子、C1-3烷基、C1-3卤代烷基等；R3、R4、R5和R6独立地为氢原子、C1-3烷基等，但其中至少有一个为C1-3烷基或C1-3卤代烷基；X和Y独立地为C1-3烷基等；Z为氮原子或亚甲基；以及其可作为农药的盐。含有该化合物或其可作为农药的盐的农药，作为活性成分的除草剂。
• Pyrazole sulfonylurea compound and herbicide
  申请人：Kita Hiroshi

  公开号：US20100016584A1

  公开（公告）日：2010-01-21

  A pyrazole compound of the formula: where: R 1 is C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy C 1-3 alkyl, phenyl or pyridyl; R 2 is a hydrogen atom, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy or a halogen atom; R 3 , R 4 , R 5 and R 6 independently of one another are a hydrogen atom, C 1-3 alkyl or C 1-3 haloalkyl, with a proviso that at least one of R 3 , R 4 , R 5 and R 6 is C 1-3 alkyl or C 1-3 haloalkyl; and L is a hydrogen atom, chlorine atom, SH, benzylthio, chlorosulfonyl, aminosulfonyl, SO 2 N═C═O, SO 2 NHCO 2 CH 3 or SO 2 NHCONHn-C 4 H 9 . A salt of the compound that is acceptable as an agrochemical. An agrochemical containing the compound or the salt thereof as an active component. A herbicide containing the compound or the salt thereof as an active component.

  一种吡唑化合物的化学式如下：其中：R1是C1-3烷基，C1-3卤代烷基，C1-3烷氧基C1-3烷基，苯基或吡啶基; R2是氢原子，C1-3烷基，C1-3卤代烷基，C1-3烷氧基或卤原子; R3，R4，R5和R6独立地是氢原子，C1-3烷基或C1-3卤代烷基，但至少其中一个是C1-3烷基或C1-3卤代烷基; L是氢原子，氯原子，SH，苯甲硫基，氯磺酰基，氨基磺酰基，SO2N═C═O，SO2NHCO2CH3或SO2NHCONHn-C4H9。一种作为农药可接受的化合物盐。一种含有该化合物或其盐作为活性成分的农药。一种含有该化合物或其盐作为活性成分的除草剂。
• PYRAZOLE SULFONYLUREA COMPOUND AND HERBICIDE
  申请人：Nissan Chemical Industries, Ltd.

  公开号：EP1748047A1

  公开（公告）日：2007-01-31

  There is provided a novel herbicide. A pyrazole sulfonylurea compound of formula (1): wherein R1 is C1-3alkyl, etc., R2 is hydrogen atom, C1-3alkyl, C1-3haloalkyl, etc., R3, R4, R5 and R6 independently of one another are hydrogen atom, C1-3alkyl, etc., with a proviso that at least one of R3, R4, R5 and R6 is C1-3alkyl or C1-3haloalkyl, X and Y independently of each other are C1-3alkyl, etc., Z is nitrogen atom or methyne, and a salt thereof that is acceptable as an agrochemical; an agrochemical containing at least one of the compound and the salt thereof that is acceptable as an agrochemical as an active component, and a herbicide containing at least one of the compound and the salt thereof that is acceptable as an agrochemical as an active component.

  本发明提供了一种新型除草剂。一种式（1）的吡唑磺酰脲化合物： 其中R1是C1-3烷基等，R2是氢原子、C1-3烷基、C1-3卤代烷基等，R3、R4、R5和R6彼此独立地是氢原子、C1-3烷基等，但有一个限制性条件，即R3、R4、R5和R6中至少有一个是C1-3烷基或C1-3卤代烷基，X和Y彼此独立地是C1-3烷基等、Z 是氮原子或甲基，以及其可作为农用化学品的盐；含有至少一种该化合物及其盐的农用化学品，其可作为农用化学品的活性成分；以及含有至少一种该化合物及其盐的除草剂，其可作为农用化学品的活性成分。
• Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors
  申请人：ASTRAZENECA AB

  公开号：US10183947B2

  公开（公告）日：2019-01-22

  The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.

  本申请涉及式 (I) 的新型化合物 在治疗和/或预防包括心血管疾病 (CVD) 在内的临床病症方面的用途、治疗方法、含有这些化合物的药物组合物以及制备这些化合物的工艺。
• Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease
  作者：Daniel Pettersen、Johan Broddefalk、Hans Emtenäs、Martin A. Hayes、Malin Lemurell、Marianne Swanson、Johan Ulander、Carl Whatling、Carl Amilon、Hans Ericsson、Annika Westin Eriksson、Kenneth Granberg、Alleyn T. Plowright、Igor Shamovsky、Anita Dellsèn、Monica Sundqvist、Mats Någård、Eva-Lotte Lindstedt

  DOI：10.1021/acs.jmedchem.8b02004

  日期：2019.5.9

  5-Lipoxygenase activating protein (FLAP) inhibitors attenuate 5-lipoxygenase pathway activity and reduce the production of proinflammatory and vasoactive leukotrienes. As such, they are hypothesized to have therapeutic benefit for the treatment of diseases that involve chronic inflammation including coronary artery disease. Herein, we disclose the medicinal chemistry discovery and the early clinical development of the FLAP inhibitor AZD5718 (12). Multiparameter optimization included securing adequate potency in human whole blood, navigation away from Ames mutagenic amine fragments while balancing metabolic stability and PK properties allowing for clinically relevant exposures after oral dosing. The superior safety profile of AZD5718 compared to earlier frontrunner compounds allowed us to perform a phase 1 clinical study in which AZD5718 demonstrated a dose dependent and greater than 90% suppression of leukotriene production over 24 h. Currently, AZD5718 is evaluated in a phase 2a study for treatment of coronary artery disease.